Literature DB >> 16362163

Catastrophic antiphospholipid antibody syndrome following initiation of hemodialysis.

Hideki Yotsueda1, Kazuhiko Tsuruya1, Masanori Tokumoto1, Hideki Hirakata2, Mitsuo Iida1.   

Abstract

Antiphospholipid syndrome (APS) is associated with arterial and venous thrombosis, pregnancy morbidity, and thrombocytopenia. Some APS patients develop rapid and disseminated microthrombosis and are known as having catastrophic APS or CAPS. We document here a case of CAPS in a patient who presented with various clinical symptoms and serious abnormalities of blood coagulation following initiation of hemodialysis after bilateral nephrectomy due to renal cancer. The patient developed multiple organ symptoms, including melena, visual disturbances, skin eruptions, lymph node swelling, urinary tract bleeding, backache, arteriovenous fistula occlusion, and chest pain. Based on the clinical course and serological and histological examinations, a diagnosis of CAPS was established. The patient recovered by following intensive anticoagulation and steroid therapy. Although CAPS is rare, once symptoms develop the condition deteriorates rapidly. Because of the associated high mortality, early diagnosis and prompt treatment are necessary.

Entities:  

Mesh:

Year:  2005        PMID: 16362163     DOI: 10.1007/s10157-005-0387-2

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  10 in total

Review 1.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.

Authors:  W A Wilson; A E Gharavi; T Koike; M D Lockshin; D W Branch; J C Piette; R Brey; R Derksen; E N Harris; G R Hughes; D A Triplett; M A Khamashta
Journal:  Arthritis Rheum       Date:  1999-07

Review 2.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

Review 3.  Catastrophic antiphospholipid syndrome: where do we stand?

Authors:  Doruk Erkan; Ricard Cervera; Ronald A Asherson
Journal:  Arthritis Rheum       Date:  2003-12

Review 4.  The catastrophic antiphospholipid syndrome.

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

Review 5.  Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients.

Authors:  R A Asherson; R Cervera; J C Piette; J Font; J T Lie; A Burcoglu; K Lim; F J Muñoz-Rodríguez; R A Levy; F Boué; J Rossert; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  1998-05       Impact factor: 1.889

6.  The role of microvasculopathy in the catastrophic antiphospholipid syndrome: comment on the article by Neuwelt et al.

Authors:  B D Golden; H M Belmont
Journal:  Arthritis Rheum       Date:  1998-04

7.  Abdominal thrombotic and ischemic manifestations of the antiphospholipid antibody syndrome: CT findings in 42 patients.

Authors:  S Kaushik; M P Federle; P H Schur; M Krishnan; S G Silverman; P R Ros
Journal:  Radiology       Date:  2001-03       Impact factor: 11.105

8.  Catastrophic antiphospholipid syndrome masquerading as ischaemic colitis.

Authors:  Jan Steffen Jürgensen; Ralf Kettritz; Wolfgang Schneider; Herbert Koop; Thorsten Sven Hildebrand; Ulrich Frei; Kai-Uwe Eckardt
Journal:  Rheumatol Int       Date:  2003-03-29       Impact factor: 2.631

Review 9.  Thrombotic storm: when thrombosis begets thrombosis.

Authors:  C S Kitchens
Journal:  Am J Med       Date:  1998-04       Impact factor: 4.965

Review 10.  The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment.

Authors:  R A Asherson
Journal:  Lupus       Date:  1998       Impact factor: 2.911

  10 in total
  1 in total

Review 1.  Insights into the pathogenesis of catastrophic antiphospholipid syndrome. A case report of relapsing catastrophic antiphospholipid syndrome and review of the literature on ischemic colitis.

Authors:  Amelia Ruffatti; Antonia Calligaro; Carmelo S Lacognata; Anna D'Odorico; Anna Colpo; Fabrizio Cardin; Fiorella Calabrese
Journal:  Clin Rheumatol       Date:  2019-12-18       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.